Glenmark

GLENMARK

gears up for U.S. launch!🚀💊

Glenmark Pharmaceuticals Inc.

the U.S. arm of Glenmark, is set to launch its Ropivacaine Hydrochloride Injection USP in multiple strengths: ✅ 40 mg/20 mL (2 mg/mL) ✅ 150 mg/30 mL (5 mg/mL) ✅ 200 mg/20 mL (10 mg/mL) (All in Single-Dose Vials) 🧪 The product is bioequivalent and therapeutically equivalent to Naropin® by Fresenius Kabi (NDA - 020533), ensuring a trusted alternative in the local anesthetic market. 📅 Distribution kicks off in November 2025. 📊 The Naropin market generated approx. $20.9 million (IQVIA, 12 months ending Aug 2025), offering Glenmark a solid market entry. 🌍 With operations in 50+ countries, Glenmark continues strengthening its footprint across Generics, Specialty, and OTC segments. 📌 Another strategic move in the U.S. generic space— one to watch for pharma investors! 💼📈